This trial is active, not recruiting.

Condition glaucoma
Treatment three different perimeters: hfa, octopus, matrix
Sponsor University Hospital Tuebingen
Collaborator Pfizer
Start date November 2008
End date December 2013
Trial size 30 participants
Trial identifier NCT01068938, 116MIR08023, 428/2008BO1, X-SCOPE


The purpose of this study is to compare three perimetric techniques regarding progression of the visual field.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
risk of progression, Latanoprost monotherapy
three different perimeters: hfa, octopus, matrix
visual fields

Primary Outcomes

glaucoma progression
time frame: 6 month

Eligibility Criteria

Male or female participants from 18 years up to 99 years old.

Inclusion Criteria: - max. ± 8 dpt sph, max. ± 3 dpt cyl - distant visual acuity > 10/20 - isocoria, pupil diameter > 3 mm - at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio (CDR) > 0.7 / inter-eye asymmetry of CDR >0.2 / notching of the optic disc /retinal nerve fibre layer (RNFL) defects / intraocular pressure( IOP) >22 mmHg / central corneal thickness < 520 µm / advanced visual field defect stage Aulhorn III / elder than 70 years Exclusion Criteria: - pregnancy, nursing - diabetic retinopathy - asthma - HIV+ or AIDS - history of epilepsy or significant psychiatric disease - medications known to effect visual field sensitivity - infections (e.g. keratitis, conjunctivitis, uveitis) - severe dry eyes - miotic drug - amblyopia - squint - nystagmus - albinism - any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields,disc imaging or accurate IOP readings - keratoconus - intraocular surgery (except for uncomplicated cataract surgery) performed < 3 month prior to screening - history or signs of any visual pathway affection other than glaucoma - allergies with regard to topic glaucoma medication - history or presence of macular disease and / or macular edema - ocular trauma - medications known to affect visual field sensitivity

Additional Information

Official title Detection of Visual Field Defects and Scotoma Progression in Glaucomatous Optic Neuropathy, Using Short-term Intervals With Automated Scotoma-oriented Perimetry (SCOPE) and the Fast Thresholding Strategy GATE (German Adaptive Threshold Estimation)
Principal investigator Ulrich Schiefer, MD
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by University Hospital Tuebingen.